Briefing
Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial
In this non-randomized phase 2 trial, 73 patients were enrolled after complete metastasectomy for oligometastatic colorectal cancer (39 received adjuvant mFOLFOXIRI; 34 received standard care). Tumor-informed ctDNA (Signatera) at 28 days after surgery predicted shorter recurrence-free survival in both arms (HR 7.27 and 7.17), as did positivity at 7 months (HR 3.96 and 4.38). ctDNA clearance occurred in 33% of the mFOLFOXIRI group and 20% of the standard-care group. The authors reported a trend toward benefit from mFOLFOXIRI in ctDNA-positive but not ctDNA-negative patients.
- Design: Evidence level 2
- Assay: Signatera